Primary central nervous system lymphomas in immunocompetent patients

Objectives. Primary central nervous system lymphoma (PCNSL) is a rare pathology and is most often seen in immunodeficient patients. This article presents our casuistic of PCNSL in immunocompetent patients and make a literature review on this issue with focus on recent advances, investigations, and controversies in diagnosis and management of this pathology. Matherial and methods. Nine patients operated in the last years in our clinics are analysed in relation to sex, age, time of symptoms, procedures and adjuvant treatment. Posteriorly the results are compared with those in the preview literature. Results. The age ranged from 44-68 years (middle of 66 years); 62,5% of the patients were female. The mean time of symptoms, when the diagnostic was made, was 3.2 months (range 1-6 months). The most common symptoms were hemiparesis (present in 75% of the patients) headache (37.5%) seizures (25%) and ataxia (25%). The most common localization was the parietal, frontal and temporal lobe surface with 25% of the patients for each localization. Five patients (50%) were treated with stereotactic biopsy, three with surgery (37.5%) and one (12.5%) with both of them. Five patients (62,5%) were submitted to pos-operative radiotherapy as adjuvant treatment. In relation to the hystology, the most common cell type was Difuse B Cells. Conclusions. This study demonstrated that complete surgical ressection followed by radiotherapy have shown good results. In opposition to the literature, the authors regard chemotherapy as a secondary line treatment and recommend its use only in some selected cases.

Saved in:
Bibliographic Details
Main Authors: Alécio-Mattei,T., Alécio-Mattei,J., Aguiar,P.H., Ramina,R.
Format: Digital revista
Language:English
Published: Sociedad Española de Neurocirugía 2006
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-14732006000100006
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1130-14732006000100006
record_format ojs
spelling oai:scielo:S1130-147320060001000062009-05-27Primary central nervous system lymphomas in immunocompetent patientsAlécio-Mattei,T.Alécio-Mattei,J.Aguiar,P.H.Ramina,R. Brain lymphoma Immunocompetent Malignant lymphoma PCNLS Objectives. Primary central nervous system lymphoma (PCNSL) is a rare pathology and is most often seen in immunodeficient patients. This article presents our casuistic of PCNSL in immunocompetent patients and make a literature review on this issue with focus on recent advances, investigations, and controversies in diagnosis and management of this pathology. Matherial and methods. Nine patients operated in the last years in our clinics are analysed in relation to sex, age, time of symptoms, procedures and adjuvant treatment. Posteriorly the results are compared with those in the preview literature. Results. The age ranged from 44-68 years (middle of 66 years); 62,5% of the patients were female. The mean time of symptoms, when the diagnostic was made, was 3.2 months (range 1-6 months). The most common symptoms were hemiparesis (present in 75% of the patients) headache (37.5%) seizures (25%) and ataxia (25%). The most common localization was the parietal, frontal and temporal lobe surface with 25% of the patients for each localization. Five patients (50%) were treated with stereotactic biopsy, three with surgery (37.5%) and one (12.5%) with both of them. Five patients (62,5%) were submitted to pos-operative radiotherapy as adjuvant treatment. In relation to the hystology, the most common cell type was Difuse B Cells. Conclusions. This study demonstrated that complete surgical ressection followed by radiotherapy have shown good results. In opposition to the literature, the authors regard chemotherapy as a secondary line treatment and recommend its use only in some selected cases.Sociedad Española de NeurocirugíaNeurocirugía v.17 n.1 20062006-02-01journal articletext/htmlhttp://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-14732006000100006en
institution SCIELO
collection OJS
country España
countrycode ES
component Revista
access En linea
databasecode rev-scielo-es
tag revista
region Europa del Sur
libraryname SciELO
language English
format Digital
author Alécio-Mattei,T.
Alécio-Mattei,J.
Aguiar,P.H.
Ramina,R.
spellingShingle Alécio-Mattei,T.
Alécio-Mattei,J.
Aguiar,P.H.
Ramina,R.
Primary central nervous system lymphomas in immunocompetent patients
author_facet Alécio-Mattei,T.
Alécio-Mattei,J.
Aguiar,P.H.
Ramina,R.
author_sort Alécio-Mattei,T.
title Primary central nervous system lymphomas in immunocompetent patients
title_short Primary central nervous system lymphomas in immunocompetent patients
title_full Primary central nervous system lymphomas in immunocompetent patients
title_fullStr Primary central nervous system lymphomas in immunocompetent patients
title_full_unstemmed Primary central nervous system lymphomas in immunocompetent patients
title_sort primary central nervous system lymphomas in immunocompetent patients
description Objectives. Primary central nervous system lymphoma (PCNSL) is a rare pathology and is most often seen in immunodeficient patients. This article presents our casuistic of PCNSL in immunocompetent patients and make a literature review on this issue with focus on recent advances, investigations, and controversies in diagnosis and management of this pathology. Matherial and methods. Nine patients operated in the last years in our clinics are analysed in relation to sex, age, time of symptoms, procedures and adjuvant treatment. Posteriorly the results are compared with those in the preview literature. Results. The age ranged from 44-68 years (middle of 66 years); 62,5% of the patients were female. The mean time of symptoms, when the diagnostic was made, was 3.2 months (range 1-6 months). The most common symptoms were hemiparesis (present in 75% of the patients) headache (37.5%) seizures (25%) and ataxia (25%). The most common localization was the parietal, frontal and temporal lobe surface with 25% of the patients for each localization. Five patients (50%) were treated with stereotactic biopsy, three with surgery (37.5%) and one (12.5%) with both of them. Five patients (62,5%) were submitted to pos-operative radiotherapy as adjuvant treatment. In relation to the hystology, the most common cell type was Difuse B Cells. Conclusions. This study demonstrated that complete surgical ressection followed by radiotherapy have shown good results. In opposition to the literature, the authors regard chemotherapy as a secondary line treatment and recommend its use only in some selected cases.
publisher Sociedad Española de Neurocirugía
publishDate 2006
url http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-14732006000100006
work_keys_str_mv AT aleciomatteit primarycentralnervoussystemlymphomasinimmunocompetentpatients
AT aleciomatteij primarycentralnervoussystemlymphomasinimmunocompetentpatients
AT aguiarph primarycentralnervoussystemlymphomasinimmunocompetentpatients
AT raminar primarycentralnervoussystemlymphomasinimmunocompetentpatients
_version_ 1755938936767643648